Sumitomo Pharma America
55 Cambridge Parkway Suite 102W
Cambridge, MA 02142
United States
Tel: +1(508)481-6700
Website: https://www.us.sumitomo-pharma.com/
About Sumitomo Pharma America
Focus Areas
We tackle unmet patient needs in the crucial fields of psychiatry and neurology, oncology, urology, women's health, rare diseases, and cell and gene therapies.
Technology
We unlock innovative science and solutions through cutting-edge technology. Advanced in-house technology platforms and data analytics capabilities de-risk and optimize clinical and commercial programs to accelerate insights in science, research, and discovery.
Advocating for Patients
We reimagine what’s possible We see people as more than the conditions they are managing. We are unwavering in our promise to advocate for patients and their families on the things that matter most to them. This promise is central to everything we do as we pursue unprecedented medical innovation.
Heritage
We are building on a legacy With Sumitomo Pharma's 125-year legacy as our foundation, Sumitomo Pharma America was formed through the consolidation of Sumitomo Pharma’s US affiliates. Our parent company, the Sumitomo Group, is over 400 years old, with an extensive history of supporting health and wellbeing.
CONNECT
166 articles about Sumitomo Pharma America
-
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis
11/2/2023
Gedeon Richter Plc. together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH announce that the European Commission has granted approval of a Type II Variation application for RYEQO® for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
-
Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
9/11/2023
Sumitomo Pharma Co., Ltd. companies, Sumitomo Pharma America, Inc. (SMPA) and Sumitomo Pharma Switzerland (SMPS), announced today that the Phase 3 URO-901-3005 clinical study of vibegron.
-
Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids
5/17/2023
As part of National Women’s Health Week, Evidation and Myovant Sciences Ltd., a wholly owned subsidiary of Sumitovant Biopharma Ltd. announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
-
Sumitovant Biopharma Completes Acquisition of Myovant Sciences
3/10/2023
Sumitovant Biopharma Ltd. ("Sumitovant") and Myovant Sciences Ltd. ("Myovant") announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.
-
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
1/26/2023
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the third quarter of fiscal year 2022 and provided other corporate updates.
-
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
11/16/2022
Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - November 16, 2022
11/16/2022
Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
10/26/2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the second quarter of fiscal year 2022 and provided other corporate updates.
-
Myovant Sciences agreed to be acquired by Sumitovant Biopharma for $2.9 billion - three weeks after turning down a previous offer.
-
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
10/24/2022
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., and Myovant Sciences announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
-
Myovant Sciences Cancels Second Quarter Earnings Conference Call
10/24/2022
Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - October 18, 2022
10/18/2022
Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on October 26, 2022
10/14/2022
Myovant Sciences, announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.
-
Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
10/3/2022
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash.
-
Myovant Sciences formed a special committee of independent directors to assess Sumitovant Biopharma's offer after Sumitovant announced plans to acquire the company.
-
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
10/2/2022
Myovant Sciences Ltd. confirmed that it has received a preliminary, non-binding proposal from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - September 16, 2022
9/16/2022
Myovant Sciences announced that it approved equity awards for 7 new employees with a grant date of September 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences to Participate at Upcoming September 2022 Investor Conferences
9/2/2022
Myovant Sciences announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and Uneek Mehra, Chief Financial and Business Officer, will participate in the following upcoming investor conferences.
-
NCCN Announces Collaboration with Myovant Sciences and Pfizer to Support Projects to Understand and Mitigate Cardiovascular Risk in Patients with Prostate Cancer
8/30/2022
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced a collaboration with Pfizer and Myovant Sciences to fund research projects seeking to improve cardiovascular management of patients with prostate cancer being treated with androgen-deprivation therapy (ADT).
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - Aug 16, 2022
8/16/2022
Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 11 new employees with a grant date of August 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.